Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy

Patients with peritoneal metastases from colorectal cancer have a poor prognosis. If the intraperitoneal tumour load is limited, patients may be eligible for cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). This treatment has improved overall survival, but recurrence rates are high. The aim of this study was to create a preclinical platform for the development of more effective intraperitoneal chemotherapy strategies.

[1]  G. Oakley,et al.  Replication protein A, the laxative that keeps DNA regular: The importance of RPA phosphorylation in maintaining genome stability. , 2019, Seminars in cell & developmental biology.

[2]  M. Pocard,et al.  A UNICANCER phase III trial of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis. PRODIGE 7. , 2019, European Journal of Surgical Oncology.

[3]  D. Morris,et al.  The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  E. Lecona,et al.  Targeting ATR in cancer , 2018, Nature Reviews Cancer.

[5]  M. Pocard,et al.  A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. , 2018, Journal of Clinical Oncology.

[6]  Matthew D. Young,et al.  Intra-tumour diversification in colorectal cancer at the single-cell level , 2018, Nature.

[7]  T. Vogl,et al.  Increased Plasma Levels of Danger-Associated Molecular Patterns Are Associated With Immune Suppression and Postoperative Infections in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy , 2018, Front. Immunol..

[8]  Andrea Sottoriva,et al.  Patient-derived organoids model treatment response of metastatic gastrointestinal cancers , 2018, Science.

[9]  N. Aaronson,et al.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer , 2018, The New England journal of medicine.

[10]  I. B. Borel Rinkes,et al.  Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases , 2018, The British journal of surgery.

[11]  A. Aalbers,et al.  Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  J. Lukas,et al.  Replication Catastrophe: When a Checkpoint Fails because of Exhaustion. , 2017, Molecular cell.

[13]  Hans Clevers,et al.  Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening , 2016, eLife.

[14]  V. Kemmel,et al.  Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy , 2015, Annals of Surgical Oncology.

[15]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[16]  H. Rosing,et al.  Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. , 2015, International journal of pharmaceutics.

[17]  T. Chua,et al.  The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery , 2014, Journal of surgical oncology.

[18]  S. Bruin,et al.  The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study , 2014, Journal of surgical oncology.

[19]  N. Mailand,et al.  ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA , 2013, Cell.

[20]  K. Havenga,et al.  Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol , 2013, Annals of Surgical Oncology.

[21]  F. Granath,et al.  Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer , 2012, The British journal of surgery.

[22]  P. Reaper,et al.  Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. , 2011, Nature chemical biology.

[23]  N. Gusani,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis , 2010, Cancer.

[24]  S. Bruin,et al.  8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer , 2008, Annals of Surgical Oncology.

[25]  W. Oyen,et al.  Peritoneal Carcinomatosis of Colorectal Origin: Incidence and Current Treatment Strategies , 2006, Annals of surgery.

[26]  J. Beijnen,et al.  Population Pharmacokinetics and Pharmacodynamics of Mitomycin During Intraoperative Hyperthermic Intraperitoneal Chemotherapy , 2004, Clinical pharmacokinetics.

[27]  David G. Morris,et al.  Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  D. Elias,et al.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Kowalski,et al.  Hyperthermic Intraperitoneal Chemotherapy , 2005 .

[30]  G. S. Kumar,et al.  Structural and function modification of DNA by mitomycin C. Mechanism of the DNA sequence specificity of mitomycins. , 1995, Nucleic acids symposium series.